Synergo for Bladder Cancer

25/03/2026

Returned from an excellent European Association of Urology (EAU) Congress in London.
The meeting was exceptionally well organized and provided a high-quality platform for insightful discussions, knowledge exchange, and meaningful collaboration across the field.
We would like to extend our sincere thanks to everyone who took the time to visit, engage in thoughtful conversations, and express interest in the Synergo technology. The level of interaction and enthusiasm was truly appreciated.
We look forward to continuing these discussions and strengthening the connections established during the congress.

02/02/2026

Progress in therapy

A 2025 study has been published on the use of -induced (RITE) with the ® system for patients with non–muscle-invasive bladder cancer ( ) who had limited treatment options after standard therapies such as BCG. According to the authors, RITE delivers significant therapeutic benefit and durable disease control while enabling bladder preservation and reducing the need for radical cystectomy in patients with -unresponsive NMIBC.

Long-term disease control with median RFS in the overall cohort was 95.1 months.

Bladder preservation rate of 88%, including 89% in patients unresponsive to BCG.

These results reinforce the role of RITE with mitomycin‑C as a promising bladder-preserving alternative for patients with recurrent or high‑risk NMIBC.

A step forward for innovation in urological oncology — congratulations to the clinical teams contributing real‑world data to improve patient outcomes across Europe!

Mero S, Oberneder K, Weiss J, Grobet-Jeandin E, Grégoris A, Sèbe P, Shariat S, D'Andrea D. Radiofrequency induced hyperthermia in non-muscle invasive bladder cancer: Oncologic outcomes in a real-world scenario. Actas Urol Esp (Engl Ed). 2025 Jun;49(5):501746. English, Spanish. doi: 10.1016/j.acuroe.2025.501746. Epub 2025 Mar 17. PMID: 40107614.

29/01/2026

We look forward to seeing you at the upcoming EAU congress in London, UK and invite you to visit us at Booth R21

24/12/2025

As the year comes to a close, we would like to extend our sincere thanks for your continued trust and collaboration. We wish you a joyful holiday season and a healthy, successful New Year.

19/11/2025

Thrilled to see this new real-world evidence using RITE + intravesical MMC in NMIBC.
A heartfelt thank you to Prof. Shahrokh F. Shariat, Assoc. Prof. (Priv.-Doz.) Dr. David D’Andrea, Dr. Elisabeth Grobet-Jeandin, and the rest of the team for their important work with the device.
As the authors conclude:
“RITE resulted in notable antitumor activity and allows for the avoidance of more aggressive and quality-of-life-limiting therapies, such as radical cystectomy.”
Highlights at 24 months in a challenging patient group (including BCG failures, those ineligible for BCG or cystectomy): high-grade recurrence-free survival of ~74.8% and cystectomy-free survival of 93.8%.
Thank you for advancing bladder-sparing options and giving more patients hope for less invasive, quality-of-life-preserving care. 🙏
S. Mero, K. Oberneder, J. Weiss, E. Grobet-Jeandin, A. Grégoris, P. Sèbe, S. Shariat, D. D’Andrea,
Hipertermia inducida por radiofrecuencia en el cáncer de vejiga no músculo invasor: resultados oncológicos en un escenario real,Actas Urológicas Españolas, Volume 49, Issue 5, 2025, 501746,
ISSN 0210-4806
;

10/09/2025

For patients with recurrent or high-risk NMIBC, the treatment journey is often marked by uncertainty.
Synergo therapy is designed to deliver:
✅ A minimally invasive, outpatient procedure
✅ Preservation of the bladder
✅ Improved quality of life through fewer recurrences
Every patient should have access to treatments that address the cancer while also supporting quality of life after diagnosis.

08/09/2025

Standard intravesical chemotherapy faces well-known challenges: recurrence and progression rates remain high.
Synergo therapy integrates intravesical chemotherapy with radiofrequency-induced hyperthermia.
Clinical studies demonstrate:
🟡 Reduced recurrence rates
🟡 Longer disease-free intervals
🟡 A bladder-sparing approach for high-risk NMIBC patients
Learn how Synergo therapy is reshaping the future of bladder cancer treatment.

22/05/2025

Excited to be part of the 51st Annual Meeting of the Austrian Society of Urology and Andrology and the Bavarian Urological Association, starting today!

We’re looking forward to insightful discussions and meaningful connections over the coming days. If you’re attending, we warmly invite you to visit us – we’d be happy to connect and exchange ideas!

Heute startet die 51. Tagung der Österreichischen Gesellschaft für Urologie und Andrologie sowie der Bayerischen Urologenvereinigung – wir freuen uns sehr, dabei zu sein!

Wir erwarten spannende Vorträge, inspirierende Gespräche und den Austausch mit Kolleg:innen aus dem Fach. Besuchen Sie uns gerne vor Ort – wir freuen uns auf den persönlichen Kontakt und interessante Gespräche!

05/05/2025

May marks Bladder Cancer Awareness Month — an opportunity to raise awareness about a common, yet sometimes overlooked, disease.
Bladder cancer is the ninth most common cancer worldwide and the fourth most common in men. Men are affected four times more than women.
Over 600,000 new cases are diagnosed each year, and around 1.9 million people are currently living with the disease.

04/02/2025

Explore Synergo for NMIBC treatment. Maximize results with RF, chemo, and hyperthermia. Visit us at the upcoming EAU annual conference in Madrid!

11/04/2024

EAU annual conference was professional and well organized as always!! We hope you enjoyed it as much as we did and wish to thank all specialists from all over the world for expressing interest in the technology for and visiting our stand. We look forward to working with you soon.

10/01/2024

We would like to congratulate Urology Consultant Mr Ahmed Ali Alnaimi and his team at Frimley Health Trust UK, for their review update on NMIBC. We at Synergo feel privileged that our treatment modality is recognised as a leading therapeutic option in BCG-unresponsive NMIBC.

Bladder cancer encapsulates a wide spectrum of disease severities, with non-muscle invasive bladder cancer (NMIBC) representing an entirely different …